Our Products
From unregistered therapeutic goods through complex regulatory pathways to TGA-registered products,
we ensure healthcare providers and patients have reliable access to the medicines they need.
Unregistered Products
We are committed to supporting healthcare providers and patients by ensuring timely access to essential medicines, especially when registered options are unavailable or in short supply. We navigate complex regulatory pathways to deliver compliant access to unapproved or internationally registered therapeutic goods.
Special Access Scheme (SAS)
We simplify and support access to unapproved medicines under the TGA-governed SAS.
- No registered treatment available in Australia
- Critical illness requiring urgent overseas therapies
- Patient ineligible for clinical trials
We facilitate the process to ensure clinicians and patients receive necessary treatment without unnecessary delays
Section 19A (Medicine Shortage)
Addressing temporary medicine shortages with TGA-compliant alternatives.
Through Section 19A approvals, we address temporary medicine shortages by sourcing overseas-registered alternatives that meet TGA standards for safety, quality, and efficacy.
These alternatives ensure that patients continue to receive uninterrupted care, and clinicians can prescribe with confidence when local supply is compromised.
Authorised Prescriber Scheme (AP)
Streamlined access for medical practitioners to prescribe unapproved medicines.
We assist prescribers in accessing unapproved medicines under the Authorised Prescriber Scheme, which allows medical practitioners to prescribe specific unapproved medicines to defined patient groups.
This eliminates the need for individual applications for each use, streamlining the process for both practitioners and patients.
Clinical Trials
Supporting research through CTN and CTA pathways.
AlgoraeRx supports clinical research by facilitating access to therapeutic goods required under the Clinical Trial Notification (CTN) and Clinical Trial Approval (CTA) schemes.
We enable sponsors and investigators to focus on trial execution with regulatory confidence, managing the complex supply requirements.
Medicine Shortage Response
Rapid response to critical supply interruptions.
Our mission is to mitigate the effects of medicine shortages on both patients and the healthcare system. By leveraging global networks and regulatory know-how, we provide safe, effective, and timely alternatives.
We ensure patients have access to their required medications when they need them most, maintaining continuity of care during supply challenges.
Registered Products
We are a dedicated team of industry professionals committed to delivering high-quality, TGA and Medsafe NZ-registered pharmaceutical products to the Australian and New Zealand markets.
TGA-Licensed Products
Our focus is on ensuring patients and healthcare providers have reliable access to clinically validated, commercially available medicines.
With exclusive distribution rights for a growing portfolio of registered medicines, AlgoraeRx is equipped to manage the complex regulatory and logistical requirements of pharmaceutical distribution across Australia and New Zealand.
Key Features
- Full TGA and Medsafe NZ registration
- Exclusive distribution rights
- Clinically validated products
- Growing product portfolio
A subsidiary of
Algorae Pharmaceuticals
20+
Registered Patents
35+
Years of Experience
30+
Skilled People
Submit your Inquiry
Reach out to us for more product related inquiry and we will get back to you shortly.